Literature DB >> 17464461

Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease.

Masaru Sakurai1, Toshinari Takamura, Tsuguhito Ota, Hitoshi Ando, Hiroshi Akahori, Kyosuke Kaji, Motoko Sasaki, Yasuni Nakanuma, Katsuyuki Miura, Shuichi Kaneko.   

Abstract

BACKGROUND: To address the hypothesis that liver steatosis causes systemic insulin resistance, we sought to determine the liver histological feature that most strongly contributes to insulin resistance in patients with nonalcoholic fatty liver disease (NAFLD).
METHODS: Liver biopsy specimens were obtained from 131 patients with clinically suspected NAFLD. The stage, grade of nonalcoholic steatohepatitis (NASH), and level of steatosis were scored and analyzed in relation to the homeostasis model assessment of insulin resistance (HOMA-IR) and the metabolic clearance rate (MCR), measured using the glucose clamp method.
RESULTS: In the univariate analysis, the degree of hepatic steatosis (r = 0.458, P < 0.001), stage (r = 0.360, P < 0.001), and grade (r = 0.349, P < 0.01) of NASH were significantly correlated with the HOMA-IR. Multiple regression analysis adjusting for age, sex, body mass index, and each histological score showed that steatosis was significantly and independently associated with HOMA-IR (coefficient = 1.42, P < 0.001), but not with the stage (coefficient = 0.33, P = 0.307) or grade (coefficient = 0.67, P = 0.134) of NASH. Similar independent relationships were observed between steatosis and MCR, but the relationship was weaker (coefficient = -0.98, P = 0.076).
CONCLUSIONS: Steatosis of the liver, but not the stage or the grade of NASH, is associated with insulin resistance in patients with NAFLD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464461     DOI: 10.1007/s00535-006-1948-

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  42 in total

1.  Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption.

Authors:  Fabrice Lainé; Claude Bendavid; Romain Moirand; Sabrina Tessier; Michèle Perrin; Anne Guillygomarc'h; Dominique Guyader; Emmanuelle Calon; Alain Renault; Pierre Brissot; Bruno Turlin; Yves Deugnier
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

4.  Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling.

Authors:  Jörn M Schattenberg; Yongjun Wang; Rajat Singh; Raina M Rigoli; Mark J Czaja
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH.

Authors:  Yoko Yoshioka; Etsuko Hashimoto; Satoru Yatsuji; Hiroyuki Kaneda; Makiko Taniai; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2004-12       Impact factor: 7.527

7.  Genes for systemic vascular complications are differentially expressed in the livers of type 2 diabetic patients.

Authors:  T Takamura; M Sakurai; T Ota; H Ando; M Honda; S Kaneko
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

8.  Hepatocellular carcinoma arising in non-alcoholic steatohepatitis.

Authors:  Y Zen; K Katayanagi; K Tsuneyama; K Harada; I Araki; Y Nakanuma
Journal:  Pathol Int       Date:  2001-02       Impact factor: 2.534

Review 9.  Hepatocellular carcinoma with nonalcoholic steatohepatitis.

Authors:  Sayaka Mori; Takahiro Yamasaki; Isao Sakaida; Taro Takami; Eiki Sakaguchi; Teruaki Kimura; Fumie Kurokawa; Shiro Maeyama; Kiwamu Okita
Journal:  J Gastroenterol       Date:  2004       Impact factor: 7.527

10.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

View more
  16 in total

1.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.

Authors:  Kouichi Miura; Yuzo Kodama; Sayaka Inokuchi; Bernd Schnabl; Tomonori Aoyama; Hirohide Ohnishi; Jerrold M Olefsky; David A Brenner; Ekihiro Seki
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

2.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

3.  The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.

Authors:  Yumie Takeshita; Toshinari Takamura; Masao Honda; Yuki Kita; Yoh Zen; Ken-ichiro Kato; Hirofumi Misu; Tsuguhito Ota; Mikiko Nakamura; Kazutoshi Yamada; Hajime Sunagozaka; Kuniaki Arai; Tatsuya Yamashita; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  Diabetologia       Date:  2014-01-10       Impact factor: 10.122

4.  Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: a pilot study.

Authors:  Takumi Kawaguchi; Naoto Shiba; Takashi Maeda; Toru Matsugaki; Yoshio Takano; Minoru Itou; Masahiro Sakata; Eitaro Taniguchi; Kensei Nagata; Michio Sata
Journal:  J Gastroenterol       Date:  2011-02-22       Impact factor: 7.527

5.  Artemisia annua Leaf Extract Attenuates Hepatic Steatosis and Inflammation in High-Fat Diet-Fed Mice.

Authors:  Kyung Eun Kim; Keon-Hee Ko; Rok Won Heo; Chin-ok Yi; Hyun Joo Shin; Jun Young Kim; Jae-Ho Park; Sanghae Nam; Hwajin Kim; Gu Seob Roh
Journal:  J Med Food       Date:  2016-01-07       Impact factor: 2.786

6.  Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases.

Authors:  Hüseyin Saadettin Uslusoy; Selim-Giray Nak; Macit Gülten; Zeynep Biyikli
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

7.  Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis.

Authors:  Erika Hamaguchi; Toshinari Takamura; Masaru Sakurai; Eishiro Mizukoshi; Yoh Zen; Yumie Takeshita; Seiichiro Kurita; Kuniaki Arai; Tatsuya Yamashita; Motoko Sasaki; Yasuni Nakanuma; Shuichi Kaneko
Journal:  Diabetes Care       Date:  2009-10-30       Impact factor: 19.112

8.  Loss of TDAG51 results in mature-onset obesity, hepatic steatosis, and insulin resistance by regulating lipogenesis.

Authors:  Sana Basseri; Sárka Lhoták; Morgan D Fullerton; Rengasamy Palanivel; Hua Jiang; Edward G Lynn; Rebecca J Ford; Kenneth N Maclean; Gregory R Steinberg; Richard C Austin
Journal:  Diabetes       Date:  2012-09-06       Impact factor: 9.461

9.  Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria.

Authors:  Seiji Nakamura; Toshinari Takamura; Naoto Matsuzawa-Nagata; Hiroaki Takayama; Hirofumi Misu; Hiroyo Noda; Satoko Nabemoto; Seiichiro Kurita; Tsuguhito Ota; Hitoshi Ando; Ken-Ichi Miyamoto; Shuichi Kaneko
Journal:  J Biol Chem       Date:  2009-03-30       Impact factor: 5.157

10.  Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease.

Authors:  Ken-ichiro Kato; Toshinari Takamura; Yumie Takeshita; Yasuji Ryu; Hirofumi Misu; Tsuguhito Ota; Kumpei Tokuyama; Shoichiro Nagasaka; Munehide Matsuhisa; Osamu Matsui; Shuichi Kaneko
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.